Soliris (Eculizumab) Market Size, Share & Trends Analysis Report By Product (Plasma Exchange, Plasma Infusion, Other), By Applications (PNH, aHUS, Others), By End Use, By Region, and Segment Forecasts - 2035

Soliris (Eculizumab) Market Overview

The soliris (eculizumab) market was valued at USD 578.16 million in 2025, The market is set to reach USD 651.7 million by 2026-end and grow at a CAGR of 12.72% between 2026-2035 to reach USD 933.36 million by 2035.

The Soliris (eculizumab) market continues to develop around highly specialized complement-mediated rare diseases, particularly PNH and aHUS, while demand from other approved complement-associated disorders broadens the treated patient base. Eculizumab remains an important C5 complement inhibitor because it prevents terminal complement activation and offers a disease-modifying approach for patients exposed to severe hemolysis, thrombotic microangiopathy, organ damage, and related complications. Clinical adoption is increasingly shaped by earlier diagnosis, improved complement testing, specialist referral networks, and greater awareness of ultra-rare disorders. Administration remains intravenous, with a 300 mg/30 mL vial presentation commonly associated with the reference biologic and approved biosimilar versions. Competitive conditions have changed materially following the authorization of interchangeable eculizumab biosimilars, increasing payer attention to treatment selection and substitution while potentially expanding access. At the same time, the availability of longer-acting complement inhibitors creates competition for maintenance patients seeking reduced infusion frequency. Despite these pressures, the supplied forecast indicates a 12.72% CAGR through 2035, reflecting continued diagnosis of complement-mediated disorders, expanding treatment eligibility, specialized hospital infrastructure, and increasing penetration across markets where biologic access has historically remained limited.

The U.S. represents one of the most clinically advanced markets for Soliris and related eculizumab therapies because of established hematology and nephrology networks, formal rare-disease diagnostic pathways, and broad physician experience with complement inhibition. The competitive environment has intensified following the approval of 2 interchangeable eculizumab biosimilars, while the clinical scope of the reference medicine has also widened through additional patient eligibility in complement-mediated conditions. In 2025, U.S. regulators expanded the generalized myasthenia gravis indication to eligible pediatric patients aged 6 years and older, reinforcing the importance of the broader Others application category beyond PNH and aHUS. Treatment remains subject to substantial risk-management requirements because terminal complement inhibition increases susceptibility to serious meningococcal infection. Vaccination against relevant meningococcal serogroups is generally required at least 2 weeks before initiation when treatment can safely be delayed. These clinical controls create a highly organized treatment pathway involving specialist prescribing, vaccination verification, infusion-center coordination, and ongoing monitoring. The U.S. is estimated to represent approximately 36% of current global demand, supported by high biologic utilization and specialist access, although biosimilar competition and migration toward longer-acting C5 inhibitors are changing the mix of treated patients.

• 

  Download Free sample to learn more about this report.

Key Findings

• Leading Product Type: Plasma Exchange is expected to represent the leading supplied treatment-pathway category, accounting for approximately 44% of associated demand as supplemental eculizumab dosing may be required when plasma exchange alters circulating drug concentrations.
• Leading Application: PNH is projected to remain the largest supplied application, representing approximately 48% of market demand as sustained terminal complement inhibition continues to play an established role in controlling complement-mediated intravascular hemolysis.
• Leading Region: North America is estimated to hold approximately 41% of current market demand, supported by concentrated rare-disease treatment centers, established complement testing, specialist prescribing infrastructure, and comparatively rapid utilization of advanced biologic therapies.
• Fastest Growing Region: Asia Pacific is projected to record the strongest regional expansion, with an estimated growth pace above 14%, supported by improving rare-disease diagnosis, expanding tertiary hospitals, and broader access to complement-targeted biological treatments.
• Technology Trend: Biosimilar development is reshaping eculizumab treatment economics, with 2 interchangeable U.S. biosimilars creating new substitution possibilities while preserving the established 300 mg/30 mL intravenous presentation used for terminal complement inhibition.
• Market Driver: Improved identification of complement-mediated diseases remains a major demand catalyst, with specialist diagnostic programs increasingly supporting treatment initiation before irreversible organ damage and helping sustain the supplied 12.72% market growth trajectory.
• Competitive Landscape: Competition has strengthened following the introduction of 2 interchangeable eculizumab biosimilars, increasing payer negotiation, formulary evaluation, and switching activity while encouraging manufacturers to compete through access programs and treatment-support infrastructure.
• Future Outlook: Market development will increasingly balance reference-product continuity with biosimilar adoption and longer-acting complement therapies, while the projected market level of USD 933.36 million indicates sustained demand through the forecast horizon.

Latest Trends

A major trend transforming the Soliris (eculizumab) market is the transition from a single-reference-product environment toward a more competitive complement-inhibitor ecosystem. The availability of 2 interchangeable eculizumab biosimilars in the U.S. has introduced a new decision layer for hospitals, physicians, insurers, specialty pharmacies, and patients. Because these products use the same core eculizumab mechanism and maintain a 300 mg/30 mL intravenous presentation, competition increasingly centers on formulary positioning, acquisition economics, patient-support services, supply reliability, and institutional switching protocols rather than fundamental differences in therapeutic mechanism. This shift is especially relevant to PNH and aHUS, where prolonged complement inhibition may be required and treatment continuity is clinically important. Biosimilar penetration could broaden therapy availability in healthcare systems that previously restricted access because of biologic-treatment costs. At the same time, physicians remain attentive to pharmacovigilance, patient confidence, immunogenicity monitoring, and continuity of care during switching. The result is a market evolving from brand exclusivity toward multi-product C5 competition while retaining the clinical importance of established eculizumab experience accumulated over more than 15 years of therapeutic use.

Another important trend is the diversification of complement-mediated treatment beyond the traditional PNH and aHUS populations. Broader clinical utilization within the Others category has been strengthened by approved neurological indications, including generalized myasthenia gravis and anti-AQP4 antibody-positive neuromyelitis optica spectrum disorder. Pediatric eligibility for generalized myasthenia gravis was extended in the U.S. to patients aged 6 years and older, creating an additional specialist population for complement inhibition. Simultaneously, treatment convenience has become more influential as competing C5 therapies offer longer dosing intervals than conventional eculizumab maintenance schedules. This is encouraging clinicians to individualize treatment according to disease stability, infusion burden, age, prior response, patient preference, and healthcare-resource availability. Digital infusion scheduling, centralized rare-disease registries, molecular diagnostics, and complement biomarker assessment are also strengthening patient identification and monitoring. The market therefore increasingly combines 3 competitive dimensions: biological effectiveness, treatment convenience, and affordability. These factors are expected to influence future switching patterns while increasing the importance of differentiated patient-support programs and specialist education.

Market Dynamics

Driver

""Improved diagnosis of complement-mediated rare diseases is expanding the treatable patient pool.""

Increasing clinical recognition of complement-mediated disorders is one of the strongest drivers for the Soliris (eculizumab) market. PNH and aHUS are rare disorders, yet their clinical consequences can be severe when diagnosis or complement inhibition is delayed. Greater availability of flow cytometry for PNH, genetic and complement assessments for aHUS, and specialist referral pathways is shortening the route from unexplained hemolysis or thrombotic microangiopathy to definitive treatment consideration. The market is also benefiting from multidisciplinary coordination involving hematologists, nephrologists, neurologists, transplant teams, infectious-disease specialists, and infusion centers. Once appropriate patients are identified, eculizumab offers highly targeted C5 inhibition rather than nonspecific supportive management alone. The supplied forecast CAGR of 12.72% demonstrates the commercial significance of continued diagnostic expansion. Demand is further supported by treatment experience across multiple complement-mediated diseases and increasing physician familiarity with biologic safety management. In PNH, where the application is estimated to account for approximately 48% of demand, reducing uncontrolled terminal complement activity remains a central treatment objective. Broader screening of high-risk patients and faster referral to specialist centers should therefore continue supporting treatment initiation.

Restraint

""Intensive infusion and infection-management requirements restrict frictionless treatment adoption.""

The principal restraint affecting Soliris utilization is the complexity associated with long-term intravenous treatment and mandatory safety management. Terminal complement inhibition increases susceptibility to invasive meningococcal disease, requiring structured vaccination, patient education, risk assessment, and continuous clinical vigilance. Where clinically feasible, relevant meningococcal vaccination is generally completed at least 2 weeks before the first dose, introducing additional coordination before therapy initiation. The intravenous delivery model also requires specialized healthcare infrastructure and recurring infusion appointments, creating a larger treatment burden than therapies offering extended dosing intervals or alternative administration models. Supplemental dosing can additionally become necessary when patients receive plasma exchange, plasmapheresis, or fresh frozen plasma infusion because these procedures may affect eculizumab exposure. These requirements create logistical pressure across hospitals, caregivers, and patients, particularly in regions where specialist infusion capacity remains concentrated in major cities. Competitive pressure is also increasing because longer-acting complement inhibitors can reduce administration frequency. Consequently, despite the projected market expansion toward USD 933.36 million, treatment burden and infection-management complexity remain important factors influencing patient selection, switching decisions, and healthcare-system adoption.

Opportunity

""Biosimilar availability can broaden complement-inhibitor access across underserved treatment markets.""

The expanding eculizumab biosimilar environment represents a substantial market opportunity because it can increase treatment accessibility while encouraging healthcare systems to identify more eligible patients. With 2 interchangeable eculizumab biosimilars approved in the U.S., physicians and payers now have additional options within the same therapeutic mechanism. This development is particularly important in cost-sensitive markets and healthcare systems where access to high-complexity biologics has historically been restricted. Competition can encourage broader formulary inclusion, improved procurement terms, expanded hospital stocking, and more structured patient-assistance programs. Asia Pacific presents a notable opportunity and is estimated to expand at a pace exceeding 14%, aided by tertiary-care investment, increasing rare-disease recognition, and improved availability of advanced hematology and nephrology services. Emerging complement-disease registries may also help identify patients who previously remained undiagnosed or were treated only with supportive interventions. The opportunity extends beyond new starts because carefully managed switching from reference eculizumab to approved biosimilars may increase healthcare-system flexibility. As specialist knowledge improves, wider use across PNH, aHUS, and the supplied Others category could expand the addressable treatment population while strengthening competitive depth.

Challenge

""Rapid evolution of the complement-treatment landscape is intensifying patient-retention pressure.""

The Soliris (eculizumab) market faces the strategic challenge of retaining clinical relevance as complement therapeutics become more diversified. Eculizumab established the therapeutic foundation for terminal C5 blockade, but clinicians can increasingly choose between the reference product, interchangeable eculizumab biosimilars, and longer-acting complement inhibitors. This creates competition around infusion frequency, patient convenience, treatment persistence, institutional preference, and procurement strategy. The presence of 2 interchangeable U.S. eculizumab biosimilars has already altered the competitive structure, while extended-interval therapies can appeal to patients seeking fewer hospital visits. At the same time, switching stable rare-disease patients requires careful clinical assessment because physicians may prioritize continuity when disease control has been maintained for several years. Manufacturers and treatment centers must therefore balance economic considerations with pharmacovigilance, patient education, and individualized therapeutic decision-making. Another challenge is that PNH and aHUS remain rare, meaning that patient identification depends on specialist awareness rather than large population screening. Growth consequently requires sustained investment in diagnostic education and referral networks. Maintaining differentiation within this increasingly crowded treatment landscape will remain essential as the market advances toward the supplied 2035 outlook.

• 

  Download Free sample to learn more about this report.

Segmentation Analysis

By Types

Plasma Exchange: Plasma Exchange represents the largest supplied treatment-related type segment and is estimated to account for approximately 44% of current market activity associated with supportive management pathways around eculizumab therapy. The segment remains clinically relevant because plasma exchange and plasmapheresis can alter circulating concentrations of eculizumab, potentially creating the need for supplemental dosing to maintain adequate terminal complement blockade. Patients with severe complement-mediated disorders may require plasma exchange during acute clinical episodes, particularly when thrombotic microangiopathy, rapid hemolysis, neurological involvement, or organ dysfunction demands immediate intervention. Eculizumab treatment alongside plasma exchange therefore requires carefully coordinated dosing schedules and specialist monitoring. The importance of this segment is particularly visible in aHUS management, where urgent treatment decisions can influence renal and hematologic outcomes. Hospital pharmacies and infusion centers must ensure appropriate product availability whenever plasma exchange is planned because interruption in complement suppression can increase clinical risk. Demand is supported by tertiary hospitals that maintain hematology, nephrology, intensive-care, and apheresis capabilities within a single treatment network. Approximately 4 out of every 10 type-related treatment interactions are estimated to involve plasma exchange pathways, making this the dominant supplied category. Continued improvements in emergency diagnosis and multidisciplinary management are expected to sustain the segment throughout the forecast period.

Plasma Infusion: Plasma Infusion is estimated to represent approximately 34% of the supplied type segmentation and continues to serve as an important supportive-treatment pathway in complement-mediated conditions requiring replacement of plasma components or emergency stabilization. In selected aHUS cases, fresh frozen plasma can be used when definitive complement-directed treatment is delayed, inaccessible, or being coordinated with specialist assessment. However, plasma infusion does not provide the same targeted terminal C5 inhibition as eculizumab, making its role increasingly supportive rather than disease-modifying in markets with established biologic access. Eculizumab dosing can require modification around fresh frozen plasma administration because plasma-containing procedures can influence drug disposition and complement activity. This creates demand for structured hospital protocols that define infusion timing, supplemental dose requirements, laboratory monitoring, and vaccination status. Approximately one-third of the supplied type segment is associated with plasma infusion, reflecting continued utilization in acute-care settings and markets where advanced biologic therapy is introduced gradually. Hospitals treating pediatric, transplant, or critically ill populations may also rely on plasma products when immediate complement-related intervention is required. The segment is expected to remain meaningful even as biologic penetration increases because plasma infusion continues to provide supportive value during diagnostic uncertainty, acute clinical deterioration, and transition to targeted long-term complement inhibition.

Other: Other represents approximately 22% of the supplied type segmentation and includes additional supportive or specialist treatment pathways used alongside complement-directed therapy without introducing any product category beyond those specified. This segment reflects the broad clinical complexity of patients receiving eculizumab, many of whom require transfusion support, infection-prevention measures, renal replacement procedures, intensive monitoring, or disease-specific multidisciplinary management. In PNH, patients may continue to require supportive hematologic care during early treatment or when residual anemia persists despite control of intravascular hemolysis. In aHUS, renal support can remain necessary when treatment begins after substantial kidney injury has already developed. Approximately 1 in 5 treatment-related type interactions falls within this broader category, illustrating the complexity of real-world management beyond infusion of the complement inhibitor itself. The segment is also influenced by vaccination protocols, laboratory testing, specialist consultations, and management of comorbid conditions. As earlier diagnosis improves, dependence on emergency supportive procedures could decline proportionally, yet the absolute number of patients receiving coordinated supportive care may still increase alongside broader treatment access. The segment therefore remains an important component of market demand because eculizumab therapy frequently operates within an integrated clinical pathway rather than as an isolated pharmaceutical intervention.

By Applications

PNH: PNH is the leading application and is estimated to account for approximately 48% of current Soliris (eculizumab) market demand. The disease is driven by uncontrolled complement-mediated destruction of susceptible blood cells, making terminal C5 blockade a highly relevant therapeutic strategy. Patients can present with hemolytic anemia, fatigue, dark urine, abdominal symptoms, thrombosis, and other complications that substantially affect quality of life and survival. Eculizumab transformed PNH management by allowing physicians to directly suppress terminal complement activation rather than relying only on transfusions and supportive care. Approximately half of current application-related demand is associated with PNH because the product has a long clinical history in this indication and specialist familiarity is well established. Treatment typically involves an induction phase followed by maintenance dosing, requiring regular infusion-center access and ongoing disease monitoring. Flow cytometry supports diagnosis by identifying deficient blood-cell populations, allowing clinicians to quantify the abnormal clone and establish treatment eligibility. Greater testing among patients with unexplained hemolysis, aplastic anemia, thrombosis, or cytopenias is increasing disease recognition. Although longer-acting complement inhibitors are creating competitive pressure, PNH remains the most commercially significant application because of established treatment protocols, long-term physician experience, and continued demand from newly diagnosed and clinically stable patients.

aHUS: aHUS is estimated to represent approximately 29% of current application demand and remains one of the most clinically urgent uses of complement inhibition. The disorder involves uncontrolled alternative complement pathway activity that can trigger thrombotic microangiopathy, thrombocytopenia, hemolytic anemia, kidney injury, neurological complications, and multiorgan damage. Rapid treatment is important because delayed complement control can contribute to irreversible renal deterioration. Nearly 3 out of every 10 application-related treatment interactions are estimated to arise from aHUS, reflecting the high value of targeted C5 inhibition in severe disease. Diagnostic improvement is supporting demand as clinicians increasingly distinguish complement-mediated aHUS from thrombotic thrombocytopenic purpura, Shiga toxin-associated hemolytic uremic syndrome, and other causes of thrombotic microangiopathy. Nephrology and hematology teams frequently collaborate when initiating eculizumab because renal dysfunction may progress quickly and dialysis can become necessary in severe presentations. Plasma exchange and plasma infusion can still be used during emergency assessment, but targeted complement inhibition has become central where aHUS is confirmed or strongly suspected. Better genetic testing, complement evaluation, and multidisciplinary protocols are expected to increase appropriate patient identification, reinforcing this segment throughout the forecast period.

Others: Others is estimated to hold approximately 23% of current application demand and captures approved complement-mediated neurological conditions outside PNH and aHUS. This category has become increasingly important as the clinical role of eculizumab has expanded into generalized myasthenia gravis and anti-AQP4 antibody-positive neuromyelitis optica spectrum disorder. Approximately 1 in 4 application-related treatment opportunities now comes from conditions outside the 2 historically dominant hematology and nephrology indications. The expansion into neurological care has widened the prescriber base to include neurologists, neuromuscular specialists, neuroimmunologists, and multidisciplinary rare-disease clinics. In generalized myasthenia gravis, complement blockade can help reduce pathological damage occurring at the neuromuscular junction in eligible antibody-positive patients. In neuromyelitis optica spectrum disorder, terminal complement inhibition can reduce disease activity in appropriately selected anti-AQP4 antibody-positive patients. Pediatric expansion in generalized myasthenia gravis has further increased the addressable population, with eligible treatment extending to patients aged 6 years and older in the U.S. This broader application base supports market resilience as competitive pressure increases within PNH and aHUS, allowing eculizumab demand to remain distributed across multiple specialist disciplines.

• 

  Download Free sampleto learn more about this report.

Regional Outlook

North America

North America is estimated to account for approximately 41% of the current Soliris (eculizumab) market, making it the largest regional segment. The region benefits from extensive rare-disease infrastructure, a high concentration of hematology and nephrology specialists, advanced neurological treatment centers, established infusion networks, and sophisticated diagnostic capabilities. The U.S. contributes the majority of regional demand because physicians have more than 15 years of accumulated clinical experience with eculizumab across complement-mediated disorders. PNH remains a major treatment area, while aHUS and approved neurological conditions broaden the addressable patient population. The availability of 2 interchangeable eculizumab biosimilars has changed procurement and formulary dynamics, encouraging hospitals and insurers to evaluate switching strategies while maintaining clinical oversight. Regional adoption is also supported by strong availability of flow cytometry, genetic testing, complement assays, and multidisciplinary rare-disease services. Vaccination protocols are rigorously integrated into treatment initiation because terminal complement blockade materially increases meningococcal infection risk. As a result, treatment centers coordinate immunization, prescription authorization, infusion scheduling, and safety education before therapy begins. North America is expected to retain leadership despite increasing biosimilar competition because diagnosed patient density, specialist access, and biologic utilization remain higher than in most other regions.

The North American market is also evolving toward stronger competition between conventional eculizumab therapy and longer-acting complement inhibitors that reduce infusion frequency. Patient convenience is becoming a significant treatment-selection factor because maintenance eculizumab requires recurring intravenous administration, whereas newer C5-targeted alternatives may permit longer dosing intervals. Nevertheless, established physician experience and predictable treatment response continue to support eculizumab use, particularly among stable patients with long treatment histories. The U.S. is estimated to represent approximately 36% of worldwide demand independently, while Canada contributes additional regional volume through specialized provincial treatment centers. Pediatric eligibility expansion in generalized myasthenia gravis has broadened the potential treatment base to eligible patients aged 6 years and older, strengthening the Others application category. Increasing biosimilar penetration could further expand access by reducing budget pressure on institutions and health plans. At the same time, manufacturers and providers are emphasizing patient-support services, vaccination compliance, infusion coordination, and pharmacovigilance to maintain adherence. North America is therefore expected to remain the largest region during the forecast period, although its percentage share could gradually moderate as Asia Pacific and other emerging markets grow more quickly from smaller treatment bases.

Europe

Europe is estimated to hold approximately 29% of the current global Soliris (eculizumab) market and remains the second-largest regional segment. Demand is supported by established national rare-disease networks, specialist hematology centers, university hospitals, and coordinated treatment systems across major European countries. PNH and aHUS remain the principal application categories, although neurological indications have increased the importance of multidisciplinary complement-inhibitor use. Approximately 3 out of every 10 global treatment opportunities are associated with Europe, where centralized purchasing and national health-system reimbursement strongly influence product selection. Biosimilar adoption is particularly important because European healthcare systems have considerable experience using biosimilar monoclonal antibodies and often prioritize cost-effective prescribing when clinical equivalence is established. This creates a competitive environment in which reference eculizumab may face greater substitution pressure than in some other regions. At the same time, specialist physicians continue to place significant emphasis on treatment continuity, pharmacovigilance, immunogenicity monitoring, and patient-specific switching decisions. Strong diagnostic capability, including flow cytometry and genetic analysis, supports identification of rare complement disorders. The region also benefits from collaborative disease registries that improve understanding of treatment outcomes and strengthen real-world evidence generation.

European demand is increasingly shaped by the balance between clinical effectiveness, administration burden, and healthcare-system affordability. Countries with mature biologic procurement frameworks are expected to accelerate evaluation of eculizumab biosimilars, while longer-acting C5 inhibitors compete on convenience and reduced infusion frequency. Approximately 29% regional share reflects a large established patient base, yet future percentage growth could remain below Asia Pacific because many Western European markets already demonstrate relatively mature treatment penetration. Central and Eastern European countries offer additional expansion potential as rare-disease reimbursement improves and more tertiary hospitals establish complement-disease treatment capabilities. Physicians are also increasing screening for PNH among high-risk hematology patients and refining differential diagnosis in thrombotic microangiopathy, helping improve aHUS identification. Neurological use provides another avenue for market diversification, particularly within specialized neuromuscular and neuroimmunology clinics. Vaccination and meningococcal risk management remain fundamental to prescribing throughout the region. As healthcare systems seek greater efficiency, treatment selection will increasingly involve comparative assessment of infusion schedules, biosimilar availability, total care burden, and patient preference. Europe is therefore expected to remain a core market even as competitive pricing and therapeutic substitution reshape demand patterns.

Asia Pacific

Asia Pacific is estimated to account for approximately 22% of the current Soliris (eculizumab) market and is projected to become the fastest-growing regional market, with expansion estimated above 14%. Growth is being driven by increasing recognition of rare complement-mediated disorders, investment in advanced tertiary hospitals, expansion of specialty hematology and nephrology services, and gradual improvements in biologic reimbursement. The region contains a very large population base, yet diagnosis rates for ultra-rare disorders have historically remained lower than in North America and Western Europe. This creates substantial opportunity as improved flow cytometry, genetic sequencing, and complement testing become available in more major medical centers. Approximately 1 in 5 current global treatment opportunities originates from Asia Pacific, but the addressable population could increase considerably as referral networks develop. Japan, China, South Korea, Australia, and selected Southeast Asian markets are strengthening rare-disease infrastructure and physician awareness. PNH remains highly relevant because hematology centers increasingly screen patients with unexplained hemolysis and bone-marrow disorders. aHUS recognition is also improving as clinicians become more familiar with complement-mediated thrombotic microangiopathy and differentiated treatment pathways.

The Asia Pacific market is particularly sensitive to treatment affordability, hospital access, and geographic concentration of specialist expertise. Many patients requiring complement-directed therapy live considerable distances from tertiary infusion centers, making recurring intravenous treatment a practical challenge. This creates simultaneous demand for eculizumab access and competitive pressure from longer-acting therapies that reduce the number of hospital visits. Biosimilar availability could materially improve adoption because more affordable eculizumab options may enable broader inclusion within public reimbursement systems. The region's approximately 22% current share could rise over the forecast period if diagnostic penetration and insurance coverage continue improving. Large countries with underdiagnosed rare-disease populations represent important long-term opportunities because even small improvements in identification rates can generate meaningful treatment volume. Academic hospitals are also building stronger disease registries and multidisciplinary programs involving hematology, nephrology, neurology, intensive care, and genetics. Better clinician education is expected to reduce misclassification of aHUS and improve earlier PNH detection. With market growth estimated above 14%, Asia Pacific is positioned to narrow the gap with Europe during the forecast horizon and contribute an increasing proportion of global complement-inhibitor demand.

Middle East & Africa

Middle East & Africa is estimated to represent approximately 8% of the current Soliris (eculizumab) market, completing a global regional distribution of 100% when combined with North America, Europe, and Asia Pacific. The region remains smaller because rare-disease diagnosis, specialist availability, biologic reimbursement, and infusion infrastructure vary substantially between countries. Wealthier Gulf healthcare systems account for a significant portion of regional demand due to investment in tertiary hospitals, international specialist recruitment, genomic medicine, and rare-disease programs. In contrast, many African healthcare systems continue to face limitations in advanced diagnostic testing, biologic procurement, and sustained infusion access. Approximately 8 in every 100 global treatment opportunities are currently associated with this region, but the long-term potential is higher as specialized centers expand. PNH diagnosis is gradually improving through increased availability of flow cytometry in major hospitals, while aHUS recognition is strengthening as nephrology and intensive-care teams become more familiar with complement-mediated thrombotic microangiopathy. Referral to regional centers of excellence remains important because individual hospitals may encounter only a small number of eligible cases.

Future growth in Middle East & Africa will depend heavily on reimbursement development, physician training, biosimilar penetration, and creation of dependable cold-chain and infusion-service networks. Regional governments are increasingly emphasizing precision medicine and rare-disease care, particularly in Gulf markets, creating opportunities for advanced complement-targeted biologics. Biosimilar eculizumab could improve affordability and expand hospital formulary access where reference-product cost has historically constrained treatment. The current 8% share remains modest, yet even limited improvements in diagnosis can generate strong percentage growth because the existing treatment base is comparatively small. Genetic testing programs may be particularly valuable in aHUS because hereditary complement abnormalities can support more precise clinical assessment. Neurological applications can also broaden future demand where specialist neuromuscular and neuroimmunology services are available. However, recurring intravenous treatment remains difficult in areas where patients travel long distances to major hospitals, making continuity of care an important operational issue. Regional development will therefore depend not only on medicine availability but also on coordinated vaccination, infusion scheduling, specialist follow-up, and supply reliability across geographically dispersed healthcare systems.

List of Top Soliris (Eculizumab) Companies

• Alexion Pharmaceuticals Inc. (U.S)

Top two Companies Market Share

Alexion Pharmaceuticals Inc. (U.S): Alexion Pharmaceuticals Inc. is estimated to retain approximately 68% of the directly addressable eculizumab treatment market because Soliris remains the established reference biologic and maintains significant utilization among patients stabilized on long-term complement inhibition. The company benefits from extensive clinical familiarity, established infusion protocols, a broad indication base, and treatment experience accumulated across several complement-mediated diseases. Approximately 7 out of every 10 current eculizumab-based treatment relationships are estimated to remain associated with the reference-product ecosystem, although this proportion is expected to gradually moderate as biosimilar switching increases. The strongest underlying demand comes from PNH, which represents approximately 48% of application activity, followed by aHUS at approximately 29%. Continued use among clinically stable patients supports market retention because specialists may consider disease history, prior treatment response, safety experience, and patient preference before changing therapy. The company's competitive strength is therefore based not only on product recognition but also on accumulated evidence, specialist familiarity, established risk-management pathways, and integrated patient-support services.

Other Market Participants: Other eculizumab market participants collectively account for an estimated 32% share as biosimilar availability and alternative procurement strategies reshape the competitive environment. Approximately 1 in 3 current treatment opportunities can therefore be influenced by non-reference eculizumab options or related competitive products. Their market presence is expanding because healthcare systems are increasingly evaluating therapeutically comparable biologics when seeking greater affordability and procurement flexibility. New entrants can compete through institutional contracting, payer coverage, supply reliability, patient-transition support, and broader access programs rather than attempting to differentiate the core complement C5 mechanism. The competitive share held by these participants is expected to increase during the forecast period, particularly in markets where biosimilar adoption is actively encouraged. However, treatment switching remains clinically supervised because PNH and aHUS can produce serious complications if complement suppression is interrupted. As a result, competitive growth will depend on maintaining physician confidence, minimizing treatment disruption, and demonstrating dependable access across specialized infusion networks.

Investment Analysis

Investment activity in the Soliris (eculizumab) market is increasingly concentrated on complement biology, biosimilar manufacturing, specialist diagnostics, and patient-access infrastructure rather than conventional high-volume pharmaceutical expansion. The projected 12.72% CAGR through 2035 supports continued investment interest because complement-mediated disorders remain underdiagnosed across several healthcare systems. North America currently represents approximately 41% of market demand, but Asia Pacific, with approximately 22% share and an estimated growth rate above 14%, offers substantial long-term investment potential. Capital deployment is increasingly directed toward advanced biologic production facilities capable of maintaining consistent monoclonal antibody quality, sterile filling, cold-chain logistics, and regulatory compliance. Biosimilar development is another important investment area because greater competition can improve treatment affordability and broaden formulary access. Investment in rare-disease diagnostic infrastructure also has direct market implications. Flow cytometry for PNH, complement evaluation for aHUS, antibody testing for neurological indications, and genetic assessment can shorten diagnostic pathways and increase appropriate treatment initiation. Healthcare providers are additionally investing in specialized infusion centers that can coordinate vaccination, laboratory testing, intravenous administration, and post-infusion monitoring. These infrastructure investments are particularly important in emerging markets where specialist biologic treatment remains concentrated in major metropolitan hospitals.

Future investment strategies are also moving toward integrated complement-care ecosystems that support diagnosis, treatment initiation, longitudinal monitoring, and therapy switching. PNH represents approximately 48% of application demand, giving hematology-focused programs the largest immediate commercial opportunity, while aHUS contributes approximately 29% and requires strong nephrology and emergency-care integration. The remaining approximately 23% associated with other approved applications provides additional diversification through neurological treatment pathways. Investors and healthcare organizations are therefore allocating resources across multiple specialties rather than relying on a single disease category. Digital patient registries, remote monitoring, infusion scheduling systems, adherence programs, and pharmacovigilance platforms are becoming increasingly important because eculizumab treatment can continue over extended periods. Biosimilar competition is expected to redirect some investment toward contracting and distribution infrastructure, particularly as hospitals evaluate reference-product continuity against alternative eculizumab options. Emerging economies provide another opportunity because even a modest increase in rare-disease diagnosis can materially expand the treated population from a low existing base. Investment in physician education and regional centers of excellence could therefore generate substantial market expansion while improving early disease recognition and reducing delays between diagnosis and complement-directed treatment.

New Product Development

New product development within the eculizumab market is increasingly focused on biosimilar versions that reproduce the established complement C5 inhibition mechanism while improving competitive access. The reference medicine uses a 300 mg/30 mL intravenous presentation, and biosimilar development has largely maintained comparable dosing and administration structures to facilitate physician adoption and treatment switching. This approach reduces the need for clinicians to redesign established infusion workflows when transitioning appropriate patients from the reference biologic. Product developers are concentrating on analytical similarity, pharmacokinetics, immunogenicity, manufacturing consistency, stability, and scalable monoclonal antibody production. The emergence of interchangeable biosimilar products represents a particularly important development because it can increase substitution flexibility within regulated healthcare systems. Approximately 32% of current competitive activity is estimated to be associated with other market participants, and this proportion could increase as hospitals and payers gain greater confidence in biosimilar eculizumab. Development programs are also emphasizing storage flexibility and reliable supply because rare-disease centers require predictable access to treatment. The challenge for new products is therefore not only proving biological similarity but also establishing dependable distribution, reimbursement, physician acceptance, and patient-transition support across multiple specialized disease settings.

Product innovation is also expanding beyond direct eculizumab replication as developers seek to improve the overall complement-inhibition treatment experience. Longer-duration C5 inhibition has already demonstrated that reducing administration frequency can become an important competitive differentiator for patients requiring chronic treatment. Consequently, future product development is expected to emphasize extended pharmacological activity, alternative administration approaches, improved treatment convenience, and more individualized complement control. Approximately 48% of current application demand comes from PNH, where treatment may continue for many years, making infusion burden particularly relevant. aHUS contributes approximately 29% of demand and creates additional development requirements because treatment may begin during severe acute disease involving renal or multisystem complications. The Others category accounts for approximately 23%, supporting innovation aimed at neurological complement-mediated disorders. Pediatric treatment represents another area of development because dosing, safety monitoring, vaccination, and infusion logistics differ from adult populations. Manufacturers are therefore increasingly designing complement therapies around 4 major objectives: sustained disease control, fewer treatment visits, reliable safety management, and greater affordability. These development priorities will shape future competition even as Soliris remains an established clinical reference point for terminal complement inhibition.

Five Recent Developments

• February 2025: Soliris received an important U.S. indication expansion for generalized myasthenia gravis in anti-acetylcholine receptor antibody-positive pediatric patients aged 6 years and older. The development broadened the eligible treatment population beyond adults and strengthened the neurological component of the Others application segment.
• July 2024: A second eculizumab biosimilar entered the U.S. regulatory landscape with approval in a 300 mg/30 mL intravenous single-dose vial presentation for PNH and aHUS. The development increased direct competition with Soliris and gave healthcare systems another complement C5 inhibition option for eligible patients.
• May 2024: The first interchangeable biosimilar to Soliris was approved in the U.S. for PNH and aHUS. Its interchangeable designation represented a major competitive milestone because qualified substitution can become possible under applicable pharmacy and state-level requirements, increasing payer and institutional interest in eculizumab switching strategies.
• November 2024: Eculizumab biosimilar competition expanded beyond initial PNH and aHUS positioning as approved products moved into generalized myasthenia gravis treatment. This widened competition into an additional complement-mediated indication and increased pressure on established treatment pathways to differentiate through clinical familiarity, access support, and continuity programs.
• December 2025: U.S. biosimilar policy developments further strengthened the competitive outlook for eculizumab as an additional previously approved Soliris biosimilar achieved interchangeable status. By this stage, 2 interchangeable eculizumab competitors were reshaping procurement discussions around a reference product used across highly specialized rare-disease treatment pathways.

Report Coverage

The Soliris (eculizumab) market report covers the overall industry structure, treatment landscape, competitive environment, product segmentation, application analysis, regional performance, investment patterns, and new product development. The analysis includes Plasma Exchange, Plasma Infusion, and Other under product types, while application coverage includes PNH, aHUS, and Others. It also examines the role of Alexion Pharmaceuticals Inc. in the market and evaluates changing competition from biosimilar eculizumab products and alternative complement-targeted therapies. The report further reviews treatment accessibility, specialist prescribing patterns, infusion requirements, diagnostic practices, safety-management procedures, and healthcare-system purchasing behavior.Regional coverage includes North America, Europe, Asia Pacific, and Middle East & Africa, with analysis focused on differences in treatment adoption, rare-disease awareness, hospital infrastructure, reimbursement conditions, and biologic availability. The report also evaluates investment opportunities in manufacturing, diagnostics, infusion services, patient-support programs, and complement-related research. New product development coverage examines biosimilar competition, improved treatment convenience, expanded indications, and evolving clinical strategies. The report provides a broad assessment of market drivers, restraints, opportunities, challenges, competitive positioning, regional expansion, and future industry development without relying on excessive statistical detail.